Versão HTML básica
389
Use of antifungal drugs in hematology
Rev Bras Hematol Hemoter. 2012;34(5):383-91
Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute
of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole
compared with liposomal amphotericin B for empirical antifungal
therapy in patients with neutropenia and persistent fever. N Engl J Med.
2002;346:225-34. Comment in: N Engl J Med. 2002;346(4):278-80; N
Engl J Med. 2002;346(4):289-90; N Engl J Med. 2002;346(4):222-4;
N Engl J Med. 2005; 352(4):410-4; author reply 410-4; N Engl J Med.
2002;346(22):1745-7; author reply 1745-7.
10. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner
D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M,
Holcenberg JS. Liposomal amphotericin B for empirical therapy in
patients with persistent fever and neutropenia. National Institute of
Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med.
1999;340(10):764-71.Comment in: N Engl J Med. 1999;341(15):1153;
author reply 1154-5. N Engl J Med. 2004;351(14):1445-7.
N Engl
J Med. 2002;346(22):1745-7; author reply 1745-7.
N Engl J Med.
2005;352(4):410-4; author reply 410-4.
11. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza
C,et al. Outcome predictors of 84 patients with hematologic malignancies
and Fusarium infection. Cancer. 2003;98(2):315-9.
12. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood.
2011;118(5):1216-24.
13. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C,
Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer
I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann
AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt
H, Cornely OA; Micafungin Invasive Candidiasis Working Group.
Micafungin versus liposomal amphotericin B for candidaemia and
invasive candidosis: a phase III randomised double-blind trial. Lancet.
2007;369(9572):1519-27.
14. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox
B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal
infections in patients undergoing bone marrow transplantation. N Engl J
Med 1992;326(13):845-51.Comment in: N Engl J Med. 1992;327(9):644;
author reply 645.
15. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman
AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal
infections after marrow transplantation--a prospective, randomized,
double-blind study. J Infect Dis. 1995;171(6):1545-52.
16. Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection
during remission-induction therapy for acute myeloid leukaemia.
Leukemia. 2006;20(12):2087-92.
17. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic
blood and marrow transplant recipients: evolution of risk factors after the
adoption of prophylactic fluconazole. J Infect Dis. 2000;181(1):309-16.
18. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E,
et al. Fluconazole therapy for chronic disseminated candidiasis in
patients with leukemia and prior amphotericin B therapy. Am J Med.
1991;91(2):142-50.
19. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins:
mode of action, in vitro activity and mechanisms of resistance. Expert
Rev Anti Infect Ther. 2009;7(8):981-98.
20. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M,
Blumer JL, et al. Intravenous and oral itraconazole versus intravenous
and oral fluconazole for long-term antifungal prophylaxis in allogeneic
hematopoietic stem-cell transplant recipients. A multicenter, randomized
trial. Ann Intern Med. 2003;138(9):705-13.Comment in: Ann Intern Med.
2004;140(7):579-80; author reply 581-2.Ann InternMed. 2003;138(9):I37.
21. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et
al. Itraconazole versus fluconazole for prevention of fungal infections in
patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527-
33.Comment in: Blood. 2004;104(5):1581; author reply 1582.
22. Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G, et al. A
double-blind, randomized, placebo-controlled trial of itraconazole
capsules as antifungal prophylaxis for neutropenic patients. Clin Infect
Dis. 2000;30(2):300-5.
23. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE,
Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester
R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E,
Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B;
Invasive Fungal Infections Group of the European Organisation for
Research and Treatment of Cancer and the Global Aspergillus Study
Group. Voriconazole versus amphotericin B for primary therapy of
invasive aspergillosis. N Engl J Med. 2002;347(6):408-15.Comment in:
N Engl J Med. 2002;347(25):2080-1; author reply 2080-1. N Engl J Med.
2004;350(9):950-2.
24. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR,
Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT,
Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M,
Marr KA; Blood and Marrow Transplant Clinical Trials Network.
Randomized, double-blind trial of fluconazole versus voriconazole for
prevention of invasive fungal infection after allogeneic hematopoietic
cell transplantation. Blood. 2010;116(24):5111-8.
25. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger
K, Pigneux A, Cornely OA, Ullmann AJ, Bofarull RM, de la Cámara
R, Weisser M, Liakopoulou E, Abecasis M, Heussel CP, Pineau M,
Ljungman P, Einsele H, Abecasis M, Rovira M, Martino R, de la Cámara
R, Cordonnier C, Herbrecht R, Moreau P, Gratwohl AA, Maertens J,
Cornely OA, Ljungman P, Olavarria E, Faucher C, Pigneux A, Einsele
H, Ullmann AJ, Liakopoulou E, Cordonnier C, Cornely OA, Heussel
CP, Rovira M, de la Cámara R; Voriconazole for Secondary Prophylaxis
of Invasive Fungal Infections in Patients With Allogeneic Stem Cell
Transplants (VOSIFI) study group; Infectious Diseases Working Party,
European Group for Blood and Marrow Transplantation. Voriconazole
for secondary prophylaxis of invasive fungal infections in allogeneic stem
cell transplant recipients: results of the VOSIFI study. Haematologica.
2010;95(10):1762-8. Comment in: Haematologica. 2010;95(10):1630-2.
Clin Infect Dis. 2011;53(5):iii.
26. Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu
AL, Cornet M, Greene J, Herbrecht R, Lacroix C, Grenouillet F, Raad
I, Sitbon K, Troke P Berger P, Bonnin A, Bougnoux ME, Brethon B,
BretonA, Toulouse P, Cannas G, DinhA, Kauffmann-Lacroix C, Legrand
F, Petit A, Poirot JL, Pons D, Ranque S, Ribaux P, Vekhoff A, Wyplosz B;
French Mycoses Study Group. International retrospective analysis of 73
cases of invasive fusariosis treated with voriconazole. Antimicrob Agents
Chemother. 2010;54(10):4446-50.
27. Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti
O. Challenging recommended oral and intravenous voriconazole
doses for improved efficacy and safety: population pharmacokinetics-
based analysis of adult patients with invasive fungal infections.
Clin Infect Dis. 2012;55(3):381-90.Comment in: Clin Infect Dis.
2012;55(3):391-3
28. Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, et al. Effect of
CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After
Single and Multiple Doses in Healthy Volunteers. J Clin Pharmacol. 2011
[Epub ahead of print].
29. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E,
Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in
Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis.
2011;17(10):1846-54.
30. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ,
et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients
with neutropenia. N Engl J Med 2007;356(4):348-59. Comment in: Nat
Clin Pract Oncol. 2007;4(9):512-3. Curr Infect Dis Rep. 2007;9(6):446-
7. N Engl J Med. 2007;356(21):2215; author reply 2215-8.